Longeveron Inc. (NASDAQ:LGVN) Director Sells $62,240.00 in Stock

Longeveron Inc. (NASDAQ:LGVN – Get Rating) Director Rock Soffer sold 8,000 shares of the stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $7.78, for a total value of $62,240.00. Following the completion of the transaction, the director now directly owns 676,351 shares of the company’s stock, valued at approximately $5,262,010.78. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Rock Soffer also recently made the following trade(s):

• On Friday, May 20th, Rock Soffer sold 7,500 shares of Longeveron stock. The stock was sold at an average price of $8.06, for a total value of $60,450.00.

LGVN stock traded down $0.36 on Tuesday, reaching $7.52. 122,901 shares of the company traded hands, compared to its average volume of 3,652,006. Longeveron Inc. has a one year low of $2.84 and a one year high of $45.00. The company has a market cap of $157.26 million, a P/E ratio of -8.41 and a beta of -2.05. The firm has a fifty day simple moving average of $9.15 and a 200-day simple moving average of $10.50.

Longeveron (NASDAQ:LGVN – Get Rating) last posted its quarterly earnings data on Friday, May 13th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. Longeveron had a negative return on equity of 58.76% and a negative net margin of 1,341.85%. During the same quarter last year, the firm posted ($0.18) earnings per share. As a group, sell-side analysts forecast that Longeveron Inc. will post -0.7 earnings per share for the current fiscal year.

Separately, Maxim Group began coverage on Longeveron in a research report on Thursday, March 24th. They issued a “buy” rating and a $14.00 target price for the company.

A number of hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada purchased a new position in Longeveron during the second quarter valued at $28,000. UBS Group AG lifted its position in Longeveron by 272.9% during the third quarter. UBS Group AG now owns 9,633 shares of the company’s stock valued at $34,000 after purchasing an additional 7,050 shares in the last quarter. Squarepoint Ops LLC purchased a new position in Longeveron during the fourth quarter valued at $122,000. Virtu Financial LLC purchased a new position in Longeveron during the fourth quarter valued at $137,000. Finally, TownSquare Capital LLC purchased a new position in Longeveron during the third quarter valued at $51,000. 2.20% of the stock is owned by institutional investors.

About Longeveron (Get Rating)

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors.

Featured Stories